In early 2026, Esperion Therapeutics disclosed operational progress through its Q1 10-Q filing alongside announcing a definitive merger agreement with Essence Parent Inc. The company is commercializing oral non-statin therapies targeting LDL cholesterol reduction, chiefly bempedoic acid and the combination with ezetimibe. Expansion of regulatory indications, ongoing pipeline advancements including the acquisition of Corstasis, and strengthened global partnerships position Esperion for growth in the competitive cardiovascular therapeutics landscape. Capital resources appear adequate to support near-term clinical development and commercialization despite persistent net losses and patent litigation risks.